1Church TR, Black WC, Aberle DR, et al. Results of ini- tial low-dose computed tomographic screening for lung cancer[J]. N Engl J Med, 2013, 368: 1980-1991.
2Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: A systemic re- view[J]. JAMA, 2012, 307: 2418-2429.
3Johnson BE, Kris MG, Berry LD, et al. A multicenter ef- fort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the Lung Cancer Mutation Consortium (LCMC)[J]. J Clin Oncol, 2013, 31(15 Suppl): Abstr 8019.
4Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts)[J]. J Clin On- col, 2013, 31(15 Suppl): Abstr 8019.
5Varella-Garcia M, Xu LG, Mahale S, et al. RET rear- rangements detected by FISH in "pan-negative" lung adenocareinoma[J]. J Clin Oncol, 2013, 31(15 Suppl): Abstr 8024.
6Dela Cruz Drilon AE, Wang L, Hasanovic A, et al. Screening for RET and ROS1 fusions in an enriched co- hort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in tar- geted therapy trials[J]. J Clin Oncol, 2013, 31(15 Sup- pl): Abstr 8067.
7Planchard D, Mazieres J, Riely GI, et al. Interim results of phase II study 13RFl13928 of dabrafenib in BRAF V600E mutation - positive non-small cell lung cancer (NSCLC) patients[J]. J Clin Oncol, 2013, 31(15 Suppl): Abstr 8009.
8Shaw AT, Ou SH, Bang YJ, et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearrangednon-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2013, 31(15 Suppl): Abstr 8032.
9US Food and Drug Administration: Approved drugs: Pa- clitaxel (Abraxane). http://www.fda.gov/drugs/ informa- tionondrugs/approveddrugs/ucm323668.htm.
10US Food and Drug Administration: Approved drugs: Er-lotinib, http://www, fda.gov/drugs/informationondrugs/ap- proveddrugs/ucm352317.htm.
